drugset / Trial / NCT02098239

Single Centre Study to Determine the Antibody Response to G17DT in Patients With Advanced Pancreatic Cancer.

NCT02098239

Phase 2 Completed 41 enrolled Cancer Advances Inc.
Non-randomizedOpen-labelTreatment

Summary

The study was designed to assess the effect of jaundice on the ability of G17DT to generate antibodies before and after treatment of biliary obstruction due to advances pancreatic cancer.

Timeline

Start
1999-08
Primary completion
2002-04
Completion
2002-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator G17DT Immunogen Vaccine Intramuscular